Search tips
Search criteria 


Logo of diacareAmerican Diabetes AssociationSubscribeSearchDiabetes Care Journal
Diabetes Care. 2011 August; 34(8): 1878–1884.
Published online 2011 July 16. doi:  10.2337/dc11-0035
PMCID: PMC3142024


History, genetics, pathophysiology, and clinical decision making

Studies conducted at the University of Michigan for 60 years and at the University of Chicago for approximately 25 years form the basis of this review. As no field of study can develop or progress in isolation, we have included selected investigations performed in other centers.


In the academic year 1949–1950, one of us (S.S.F.), while a first-year Fellow in Endocrinology and Metabolism at the University of Michigan (Jerome W. Conn, Division Chief), initiated a prospective, long-term study on the diagnosis, natural history, and clinical genetics of diabetes. Starting with known diabetic patients from the Diabetes Clinic, I recruited their apparently healthy and asymptomatic first-degree relatives (parents, brothers, sisters, and children) for routine oral glucose tolerance tests (OGTTs). As control subjects, I recruited young individuals, many of them students, physicians, nurses, dietitians, and their spouses, who did not have a family history of diabetes or of large newborn babies. The initial objectives were 1) to define the normal range for the OGTT, 2) to attempt to unmask the potential diabetic subjects who manifest normal glucose tolerance by the standard OGTT and determine whether the diabetogenic activity of cortisone could be used to uncover a subclinical defect in the metabolism of glucose, and 3) to carry out periodic follow-up over many years of the apparently healthy first-degree relatives of diabetic patients. In our first publication in 1954 (1), 19% of 152 relatives of known diabetic patients were found to have diabetes by OGTT and, moreover, some were as young as 10 years of age. The same prevalence of 19% was found when testing a larger sample of 438 relatives of known diabetic patients (2).

In 1960, we reported that mild, asymptomatic diabetes occurs in nonobese children, adolescents, and young adults. Their diabetic glucose tolerance and fasting hyperglycemia improved or normalized with the administration of sulfonylurea therapy (35). When I presented these results at the First International Congress of Endocrinology in Copenhagen in 1960, Professors Rolf Luft and Knud Lundbaek each remarked that they had never seen such patients and that this kind of diabetes did not exist in Europe. My response was that such diabetic subjects did not come to the physician or investigator; the investigator had to find them by testing the asymptomatic first-degree relatives of known diabetic patients.

The study of asymptomatic diabetes in young people took a new direction in 1958 when I became aware of a 70-year-old male patient who was diagnosed with diabetes at the age of 41 years (Supplementary Fig. 1, individual III-5). He was blind from diabetic retinopathy at the age of 61 years and had an amputation for peripheral vascular disease. His diabetic mother had four diabetic siblings in a sibship of nine (generation II). The proband had four diabetic siblings (in a sibship of six), the majority of whom had evidence of severe micro- and macrovascular disease as well as neuropathy. I recruited the 11 nonobese, apparently healthy and asymptomatic children of the proband for routine OGTT and thus began my studies of the RW pedigree. Seven of the 11 children, ranging in age from 11 to 30 years, were found to have abnormal glucose tolerance. The older three had fasting hyperglycemia (up to 370 mg/dL), one had a diabetic OGTT without fasting hyperglycemia, and three had impaired glucose tolerance (68). Subsequently, fasting hyperglycemia developed in these seven children. By prospective routine OGTTs, non–insulin-requiring diabetes was diagnosed in 11 of 21 members of generation V, all of whom were children of diabetic subjects in generation IV. Six members of generation VI have diabetes. Details of diagnosis, natural history, phenotypic expression, and treatment of members of the RW pedigree can be found in references 69. Repeated fluctuation between abnormal and normal glucose tolerance was shown to be part of the natural history of this type of diabetes in the RW pedigree (7).

In 1964 at the Fifth Congress of the International Diabetes Federation in Toronto, I first used the term “maturity-onset type diabetes of childhood or of the young” for this type of diabetes and emphasized its strong familial basis (10). This term was applied at that time, as the general thinking was that diabetes could be divided into two major types: juvenile-onset type (now type 1) diabetes with its explosive development to insulin dependence and occurring primarily, but not exclusively, in young people; and maturity-onset (now type 2) diabetes occurring in middle-aged and older people that could be controlled by diet and oral agents and requiring insulin only after many years.

With respect to genetics, it was believed in the 1960s that diabetes was a polygenic disorder, still applicable today for type 1 and type 2 diabetes (11). However in 1974, Robert Tattersall reported a “mild” form of diabetes in three families from King’s College Hospital in London and recognized that diabetes in these families had a dominant mode of inheritance (12). Tattersall thought he was dealing with a mild form of diabetes because in many patients, insulin therapy could be discontinued and there were fewer diabetes complications than expected, even though some retinopathy, including blindness, was described. With longer follow-up, typical severe microangiopathic and neuropathic complications developed in these families (13). Although Tattersall recognized that these patients “appeared to have maturity-onset type diabetes at an unusually early age,” he did not use the term “maturity-onset diabetes of the young” (12). Robert Tattersall spent the 1973–1974 academic years with me in Ann Arbor. On the basis of the records of the prospective study that had been ongoing in Ann Arbor since 1949, we identified, in addition to the RW pedigree, 23 other families in whom our working criteria for maturity-onset type diabetes of the young applied. We were able to differentiate between the pattern of inheritance in these families from that seen in 35 families with classical juvenile-onset type (type 1) diabetes and confirmed autosomal-dominant inheritance for the former (14). In this article, we first used the abbreviation or acronym MODY for maturity-onset diabetes of the young. These two articles (12,14) provided some of the first evidence that diabetes is genetically heterogeneous, further discussed in my Banting Memorial Lecture of 1978 (6). Robert Tattersall deserves full credit for suggesting that the familial disease previously designated in 1964 as maturity-onset diabetes of the young is inherited in a dominant fashion. Tattersall quotes Cammidge who proposed, in 1928, dominant inheritance in a mild form of familial diabetes (15). This was based entirely on the finding of glycosuria, even though assays for measuring blood glucose levels had been available for approximately a decade at the time. Thus in Cammidge’s pedigrees, one cannot distinguish between primary renal glycosuria or the type 3 form of MODY (MODY3 due to mutations in the gene encoding the transcription factor hepatocyte nuclear factor 1α), which is also characterized by renal glycosuria.

Since 1975, I have used autosomal-dominant inheritance consistently as one of the requirements for the definition of MODY. Although young age at diagnosis of diabetes is an important feature of MODY, age at diagnosis and time interval between diagnosis and insulin requirement should no longer be criteria for the definition of MODY as diagnosis may be made for the first time in subjects over the age of 25 years and also in subjects treated with insulin. For example, in the RW pedigree in which prospective testing started in generation IV, the mean age at diagnosis was 55 years in generations II and III, 35 years in generation IV, 20 years in generation V, and 11 years in generation VI.


MODY can be suspected and recognized if a type 2 diabetes–like condition occurs in two to three or more generations and the pattern of inheritance is consistent with autosomal-dominant inheritance (6,7). The latter is the hallmark of MODY and distinguishes it from type 2 diabetes. MODY can be diagnosed at a young age and frequently in childhood or early adolescence (9–14 years of age or earlier), particularly if sought by routine OGTT. Occasionally, MODY can also be found in type 1 diabetes–like families (16). By serial testing young members of the RW pedigree, we showed that there can be very slow progression from normal to impaired glucose tolerance, from impaired to diabetic glucose tolerance with normal fasting plasma glucose level (up to 18 years), and very slow progression from that state to fasting hyperglycemia (up to 27 years). Children and adolescents with MODY may also have fasting hyperglycemia at diagnosis and rapid progression to insulin requirement. Thus, there is a variable course in severity and rate of progression of hyperglycemia and decrease in insulin levels. Most members of MODY families are not obese, in contrast to patients with type 2 diabetes. However, this is not uniformly true, as discussed below. In many MODY families, typical microangiopathic and macroangiopathic complications occur in a frequency similar to the pattern seen in type 2 diabetic patients with similar degrees of hyperglycemia (6,7,17,18). In contrast to the clinical characteristics reported for the RW pedigree (MODY1) and families with MODY3 are subjects with glucokinase mutations (GCK-MODY, MODY2) who have mild fasting (110–140 mg/dL) and postprandial hyperglycemia from birth, lack of progression, and absence of insulin requirement and vascular complications.


In 1969, we first reported that some asymptomatic children, adolescents, and young adults with MODY had delayed and subnormal insulin responses to glucose (19). Low insulin responses to oral glucose in the RW pedigree were seen in diabetic and “nondiabetic carrier” subjects.

Long-term administration of sulfonylureas may induce increases in glucose-induced insulin secretion for up to 33 years in some subjects with MODY in the RW pedigree. However, in most, glucose-induced insulin secretion decreases over time (1–4% per year) (5). Some patients become unresponsive to sulfonylureas after 3–25 years and then have very small or no increase in glucose-induced insulin secretion and require insulin to normalize fasting hyperglycemia. The insulin and C-peptide levels can become so low in some MODY patients that they resemble type 1 diabetic patients and exhibit the same typical labile glucose levels.

In 1986, I reported two families (TE and H), each with four generations of diabetes consistent with autosomal dominant inheritance (20). Both families were studied in the 1970s and early 1980s. In contrast to the RW pedigree and most other MODY families, members of the TE pedigree had supernormal insulin responses to oral glucose, and members of the H pedigree had a delayed insulin response at 0.5 h of the OGTT and then a supernormal insulin response, as compared with 150 healthy control subjects. I suggested that these two families represented examples of the heterogeneity of insulin secretion in MODY. In retrospect, the high insulin response in the H family can be explained by mild obesity, as discussed later. The high insulin response in the TE family is unexplained. As these families are no longer available for genetic studies, we cannot present them as evidence of heterogeneity of insulin responses in MODY.


Genetic studies of diabetes in the RW pedigree began in 1985. Alan Permutt et al. (21) typed the insulin gene VNTR and showed that it did not cosegregate with diabetes. They also excluded linkage to the human insulin receptor gene in the RW and three other MODY pedigrees (including our H and TE families) in 1987 (22). The latter results were confirmed by Arthur Vinik in 1988 while on sabbatical in the laboratory of Graeme Bell, in addition to excluding the erythrocyte/HepG2 glucose transporter (GLUT1) and the apolipoprotein B genes (23). This latter study began my collaboration with Graeme Bell, which continues more than 23 years later.

A major breakthrough in the molecular genetics of diabetes in the RW pedigree came in 1991, when after testing more than 75 DNA markers, Graeme Bell, Nancy Cox, and colleagues (24) found that a DNA polymorphism in the adenosine deaminase gene (ADA) on the long arm of chromosome 20 cosegregated with MODY. Although the gene responsible for MODY is tightly linked to the ADA gene, it was recognized that it was not the ADA gene itself. These results were confirmed and extended by Bowden et al. (25) who in 1992 showed linkage of MODY to the marker D20S16. It took 5 years to identify the gene responsible for MODY (now called MODY1 to distinguish from other forms of MODY) in the RW pedigree. In 1996, Graeme Bell, Kazuya Yamagata, and colleagues together with Stefan Fajans (26) identified a nonsense mutation in the gene encoding the transcription factor hepatocyte nuclear factor (HNF) 4α (gene symbol, HNF4A; p.Q268×) as the cause of diabetes. At the same time, this group with Andrew Hattersley and Philippe Froguel reported that mutations in the gene encoding another transcription factor, HNF-1α (HNF1A), were responsible for MODY3 (27). Both are transcription factors involved in tissue-specific regulation of liver genes but also expressed in pancreatic islets and other tissues.

Philippe Froguel and Alan Permutt (28), and independently Andrew Hattersley (29), and their colleagues showed linkage of the glucokinase gene on chromosome 7 with MODY, suggesting that mutations in this candidate gene were another cause of MODY. Subsequently, Nathalie Vionnet, Philippe Froguel, and colleagues in collaboration with Graeme Bell identified mutations in the glucokinase gene (GCK and MODY2) (30). These latter studies highlighted the key role of glucokinase as the glucose sensor of the β-cell and its regulation of glucose-stimulated insulin secretion.

Doris Stoffers and Joel Habener in 1997 reported a five-generation Virginia family in which MODY cosegregated with a frame-shift mutation (p.P63fsX60) in the gene encoding another β-cell transcription factor, insulin promoter factor 1 (IPF1), termed MODY4 (31). The proband in that family was an infant with pancreatic agenesis, neonatal diabetes, and pancreatic exocrine dysfunction who was homozygous for this mutation. A Michigan–Kentucky family with the same mutation and which shared a common ancestor with the Virginia family was reported by us in 2010 (32). Also in 1997, Graeme Bell, Yukio Horikawa, and colleagues reported a mutation in the gene encoding the transcription factor HNF-1β (HNF1B) in a patient with MODY and early-onset kidney disease (MODY5) (33).

Genetic studies have revealed that MODY is not a single genetic entity but can have many causes. Online Mendelian Inheritance in Man lists 11 forms of MODY (Supplementary Table 1). The most common causes of MODY are mutations in HNF1A and GCK, and less commonly HNF4A, HNF1B, and INS (34). Mutations in the other genes listed in Supplementary Table 1 are quite rare. As there are families with a MODY-like phenotype of unknown cause, we anticipate that ongoing genetic studies will identify additional genes.


Prior to the identification of the genes responsible for MODY, we had suggested that MODY was a primary genetic disorder of the β-cell (19,35). The genetic studies mapping the MODY1 gene to the region of ADA allowed us to identify carriers and thus examine insulin secretion and action directly in patients with MODY1 (36).

Using the frequently sampled intravenous glucose tolerance test and Bergman’s minimal model, as well as Polonsky’s low-dose prolonged glucose infusion to measure insulin secretion rate (ISR) and pulse analysis (36), we (in collaboration with Kenneth Polonsky and Jeffrey Halter) showed that nondiabetic carriers had normal sensitivity to insulin and normal acute insulin response to intravenous glucose. However, the same subjects had decreased mean plasma C-peptide concentrations and reduced absolute amplitude of insulin secretory oscillations during prolonged glucose infusion. These responses were similar to those observed in diabetic carriers. Thus, deranged and deficient insulin secretion, and not insulin resistance, appears to be the genetic or the primary abnormality that characterizes nondiabetic carriers in the RW pedigree. Diabetes becomes manifest when additional superimposed environmental factors supervene (e.g., physiological decrease in insulin sensitivity with growth and puberty) (6,7).

Again in collaboration with Kenneth Polonsky and his colleagues, we examined the dose–response relationship between plasma glucose concentration and ISR during a graded intravenous glucose infusion (37). Nondiabetic MODY1 subjects had a defective insulin secretory response to an increase in plasma glucose concentration, and this response differed from nondiabetic MODY2 and MODY3 subjects (3740). These series of studies led us to propose that MODY is a primary genetic disorder of the pancreatic β-cell with mutations in different genes affecting glucose-stimulated insulin secretion (40).

In the 1960s, we demonstrated that amino acids and proteins are potent stimuli to insulin secretion (41). Among amino acids, arginine is the most potent stimulus to insulin and glucagon secretion. To ascertain the effects of arginine on insulin and glucagon secretion in MODY1 (42), we studied nondiabetic noncarriers, nondiabetic carriers, and diabetic carriers in the RW pedigree. There was a decrease in insulin secretion in the nondiabetic carriers in response to a constant arginine infusion that was exacerbated during the hyperglycemic clamp and in diabetic carriers. Glucagon secretion at basal glucose concentration was also decreased in both the nondiabetic and diabetic carriers. We also observed that nondiabetic carriers had a reduced amylin response to arginine that was proportional to the deficit in insulin secretion (43). There was also reduced pancreatic polypeptide (PP) secretion in diabetic and nondiabetic carriers (43). Thus, mutations in HNF4A appear to confer a generalized defect in pancreatic islet cell function involving β-, α-, and PP-cells. This generalized defect could either be due to defects in common signaling pathways, to an overall reduction in the mass of pancreatic islet cells, or a combination of both (43).


HNF-1α and HNF-4α were initially identified in the liver, where they regulate the expression of a large number of genes encoding serum proteins, including clotting factors and apolipoproteins, among others. Thus, we and others have searched for serum markers to identify patients with MODY due to HNF4A and HNF1A mutations. With George Brownlee, we measured factor IX levels in plasma and found no significant difference between carriers with MODY1 (RW pedigree) and controls (G. Brownlee, S.F.F., and G.I.B., unpublished data). In contrast, triglyceride and apolipoprotein C-III levels are significantly reduced (44,45). Moreover, the levels of apolipoproteins A-II and C-III, lipoprotein (a), and triglycerides were significantly reduced in carriers in the RW pedigree whether diabetic or nondiabetic (45), indicating that HNF-4α deficiency rather than hyperglycemia is the primary cause of these decreases. Although the levels of triglycerides and apolipoproteins are significantly decreased in HNF4A mutation carriers, there is still substantial overlap between groups, which limits their usefulness as biomarkers to identify individuals who would benefit from genetic testing.

Apolipoprotein M levels are reduced in HNF1A mutation carriers but are not a useful predictive marker (46). However, Anna Gloyn and her colleagues have recently shown that high-sensitivity C-reactive protein (hs-CRP) is lower in HNF1A-MODY than in other forms of diabetes, and measurement of hs-CRP may be useful as a prescreening tool to identify patients for genetic testing (47).


The clinical phenotype of patients with the same form of MODY can vary, as can the phenotype of individuals within a family who share the same mutation (48,49). This reflects differences in the effect of the mutation on protein functions as well as the modifying effect of environmental factors (diet, exercise, and other nongenetic factors) on genetics. This is illustrated for MODY1 by a male carrier in the RW pedigree, who at 44 years of age had normal glucose levels in all OGTTs, an age by which all other carriers had developed diabetes (26). Obesity can also modify the phenotype of carriers (32). Finally, the clinical progression can vary within MODY families and can include neonatal hypoglycemia in some subjects with MODY1 (50,51).


The majority of subjects with MODY are not obese. In the past, the presence of obesity in a diabetic subject was considered to be evidence against MODY. In 2010, we described a five-generation Michigan–Kentucky pedigree (32), ascertained through a proband with neonatal diabetes and pancreatic agenesis, that was homozygous for the IPF1 mutation p.P63fsX60 (31). By family history, we ascertained 110 individuals in this pedigree. Diabetic and nondiabetic subjects were genotyped and phenotyped where possible. There were 16 diabetic subjects who carried the IPF1 mutation and 4 in whom it could be presumed to be present. There were eight diabetic subjects who did not carry the mutation and had type 2 diabetes. Both MODY4 and type 2 diabetes in this pedigree are associated with obesity and hyperinsulinemia. Obesity and hyperinsulinemia have also been observed sporadically in MODY1, MODY3, and MODY6 subjects, and hyperinsulinemia may be a clinical feature when obesity occurs together with MODY (32). Thus, genetic testing for MODY should be considered in multigenerational families, even in the presence of obesity, especially if such families contain young diabetic members.


In 2007, Ewan Pearson, Andrew Hattersley, and colleagues reported a remarkable and previously unrecognized feature of the natural history of MODY1 (50). In a comparison of 54 mutation carriers (from 15 pedigrees with 12 different mutations) with noncarrier family members, they found a significant increase in median birth weight (790 g) with a 56% prevalence of macrosomia in carriers versus 13% in noncarriers. Transient neonatal hypoglycemia was reported in 8 of 54 neonates. Three of these infants had hyperinsulinemia.

We examined macrosomia and neonatal hypoglycemia in the RW pedigree (51). In 34 mutation carriers, birth weight was increased by a median of 751 g as compared with noncarriers. Macrosomia occurred in 59% compared with 8% in noncarriers. In both the subjects studied by Pearson et al. (51) and in the RW pedigree, macrosomia was inherited from mother (64 and 68%, respectively) and father (46 and 47%, respectively). There were only two instances of neonatal hypoglycemia in the RW pedigree. Thus, the natural history of MODY1 includes hyperinsulinemia in fetal and neonatal life, progressing to insulin-deficient diabetes in later years. The molecular basis for the differential effects of HNF-4α deficiency on β-cell function and insulin secretion in neonates and later in life and the exact timing of the switch from hyperinsulinemia to hypoinsulinemia are unknown. In this regard though, a male carrier with macrosomia had, at age 3 years, a normal OGTT but a low-normal insulin response to glucose (51).

Further analysis of macrosomia of MODY1 infants has revealed no effect of parental origin of the HNF4A mutation on birth weight and no effect of severity of macrosomia on age of diagnosis of subsequent diabetes (E.R. Pearson, S.S.F., G.I.B., and A.T. Hattersley, unpublished observations).

Macrosomia and neonatal hypoglycemia have not been associated with HNF1A mutations (50). This raises the question as to which genes are regulated by HNF4A but not by HNF1A in β-cell development.


As predicted by J.V. Neel in the premolecular genetic era (11), type 2 diabetes is a polygenic disease with superimposed precipitating environmental factors. We began our studies of MODY with the expectation that the identification of the genes responsible for MODY would provide insight into the genetics and pathophysiology of type 2 diabetes. Common variants in HNF1A and HNF1B affect risk of type 2 diabetes in large-scale meta-analyses, and common variants in HNF4A may also be associated with type 2 diabetes, at least in some populations (52,53). Despite the lack of evidence that mutations in MODY-related genes are responsible for the development of type 2 diabetes in the majority of cases, the molecular mechanisms by which variants in these genes lead to hyperglycemia may be relevant to the pathophysiology of the β-cell defects in type 2 diabetes. In this regard, defects in the metabolism of glucose in the pancreatic β-cell may be responsible, at least in part, for the impaired insulin secretion seen in patients with type 2 diabetes as it is in MODY. Thus, lessons learned from studies of MODY may improve our understanding of type 2 diabetes. Resequencing of the various MODY genes as well as the genes responsible for other monogenic forms of diabetes (dominant and recessive, syndromic and nonsyndromic) is a goal of the National Institutes of Health–funded T2-GENES Consortium, and these studies will help elucidate the role of monogenic diabetes genes in the etiology of type 2 diabetes.


When a patient who appears to have type 2 diabetes but also has a family history of multigenerational diabetes, particularly when early-onset, MODY should be suspected (see Supplementary Data, Summary of Clinical Issues in MODY). Most patients with MODY are lean, but obesity should not exclude a diagnosis of MODY. Likewise, but less commonly, when a young diabetic patient resembling type 1 diabetes is islet autoantibody negative and has measurable C-peptide levels, MODY should be suspected. Under these circumstances, genetic testing is indicated. Genetic testing will disclose whether MODY is present and will distinguish between subtypes of MODY, and thereby give clues to prognosis and treatment. Once a diagnosis for MODY is made, other family members, both diabetic and nondiabetic, should be screened for the family-specific mutation and possible abnormalities of carbohydrate metabolism. Such screening procedures are as follows, listed in ascending order of sensitivity: hemoglobin A1C (A1C), fasting plasma glucose, 2-h postglucose levels, 1-h postglucose levels, and OGTT (most sensitive) (54). Genetics counseling should be provided, especially in children.

The most common causes of MODY are mutations in HNF1A and GCK, and mutations in these two genes account for 80% (HNF1A, 58%; GCK, 22%) of cases in the U.K. (the relative frequency of GCK is higher in cases ascertained through pediatric clinics, whereas the frequency of HNF1A is higher in cases from adult clinics) (34,55). Mutations in HNF4A account for ~5% of cases and HNF1B (renal cysts and diabetes syndrome) for 2%. Mutations in other genes are very rare causes of MODY. We focus our genetic testing on mutations in HNF1A, GCK, and HNF4A and HNF1B if there is evidence of renal cysts or abnormal kidney or genital tract development.

Patients with a genetic diagnosis of HNF1A- or HNF4A-MODY can often be treated with sulfonylureas with good glycemic control. There is usually progressive deterioration in pancreatic β-cell function and/or mass in patients with these two forms of MODY (5). Our experience suggests that good control slows this decline, but there are no controlled trials to prove this and such studies are needed. A low carbohydrate diet might be helpful along with exercise to increase insulin sensitivity. Glinides may be considered in the patients with HNF1A-MODY, as this class of sulfonylureas is shorter acting and has lower risk of reactive hypoglycemia (56).

Patients with GCK-MODY generally need no treatment. In patients with gestational diabetes, treatment is required. If A1C levels are >6.5% or fasting blood glucose >126 mg/dL, some clinicians have suggested that Metformin may reduce fasting blood glucose levels. However, we have seen MODY2 patients with fasting plasma glucose in the 140–150 mg/dL range who have not progressed or developed complications for up to five decades. Otherwise, insulin is the only established treatment because both insulin secretion and hepatic glucose production are abnormal.

In the future, glucokinase activator class of drugs might be useful in GCK-MODY. Whether agonists for other gene mutations might be helpful is speculative. In Pdx1-deficient mice that develop MODY4-type diabetes, an experimental procedure has been discovered that prevents apoptotic and necrotic β-cell death and diabetes (57). Whether this procedure will be applicable to humans and other forms of MODY remains to be determined.


When we began our studies of MODY 60 years ago, very little was known about the genetics and pathophysiology of diabetes. Patients with diabetes were described as having juvenile-onset or maturity-onset diabetes. These terms have evolved to type 1 and type 2 diabetes, with insulin-dependent and non–insulin-dependent also being briefly used as the diabetes community struggled and continues to struggle with how best to define the various forms of diabetes. Monogenic forms of diabetes including MODY are now recognized as a discrete class of diabetes (58,59). MODY was initially thought to be a rare form of diabetes. We now know that MODY is very common, masquerading as type 1 diabetes or, more commonly, type 2 diabetes. The frequency of MODY among patients with diabetes is estimated to be 1–2%. The majority of MODY patients are undiagnosed or missed (34). Genetic testing for MODY is now routine and can affect correct diagnosis and treatment (60). MODY has entered the mainstream.

Supplementary Material

Supplementary Data:


This work was funded by the Biochemistry Core of the Michigan Diabetes Research and Training Center (DK-020572) from the National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Public Health Service grant M-01-RR-00042 to the General Clinical Research Center, and Clinical and Translational Science Award grant UL1-RR-024096, all at the University of Michigan. Work at the University of Chicago was funded by the U.S. Public Health Service Grant DK-020595 (University of Chicago Diabetes Research and Training Center) and by a gift from the Kovler Family Foundation.

No potential conflicts of interest relevant to this article were reported.

S.S.F. and G.I.B. contributed to the research data and discussion, wrote the manuscript, and reviewed and edited the manuscript.

The authors thank Sheri Amici (University of Michigan) and Dr. Honggang Ye (University of Chicago) for their kind patience with the authors in making this article possible.


This article contains Supplementary Data online at


1. Fajans SS, Conn JW. An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone. Diabetes 1954;3:296–302; discussion, 302–304 [PubMed]
2. Fajans SS, Conn JW. The early recognition of diabetes mellitus. Ann N Y Acad Sci 1959;82:208–218 [PubMed]
3. Fajans SS, Conn JW. Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus. Diabetes 1960;9:83–88 [PubMed]
4. Fajans SS, Conn JW. The use of tolbutamide in the treatment of young people with mild diabetes mellitus —a progress report. Diabetes 1962;11:123–126
5. Fajans SS, Brown MB. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993;16:1254–1261 [PubMed]
6. Fajans SS, Cloutier MC, Crowther RL. The Banting Memorial Lecture 1978. Clinical and etiologic heterogeneity of idiopathic diabetes mellitus. Diabetes 1978;27:1112–1125 [PubMed]
7. Fajans SS. Scope and heterogeneous nature of MODY. Diabetes Care 1990;13:49–64 [PubMed]
8. Fajans SS, Bell GI, Bowden DW. MODY: a model for the study of the molecular genetics of NIDDM. J Lab Clin Med 1992;119:206–210 [PubMed]
9. Fajans SS, Bell GI, Bowden DW, Halter JB, Polonsky KS. Maturity-onset diabetes of the young. Life Sci 1994;55:413–422 [PubMed]
10. Fajans SS, Conn JW. Prediabetes, subclinical diabetes and latent clinical diabetes: interpretation, diagnosis and treatment. In On the Nature and Treatment of Diabetes New York, NY, Excerpta Medica, 1965, p. 641–656 (Int. Cong. Ser., no. 84)
11. Neel J, Fajans SS, Conn JW, Davidson RT. Diabetes mellitus. In Genetics and the Epidemiology of Chronic Disease Washington, DC, U.S. Public Health Service, 1965, p. 105–132 (publ. no. 1163)
12. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974;43:339–357 [PubMed]
13. Tattersall RB, Mansell PI. Maturity onset-type diabetes of the young (MODY): one condition or many? Diabet Med 1991;8:402–410 [PubMed]
14. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975;24:44–53 [PubMed]
15. Cammidge PJ. Diabetes mellitus and heredity. BMJ 1928;2:738–741 [PMC free article] [PubMed]
16. Møller AM, Dalgaard LT, Pociot F, Nerup J, Hansen T, Pedersen O. Mutations in the hepatocyte nuclear factor-1α gene in Caucasian families originally classified as having type I diabetes. Diabetologia 1998;41:1528–1531 [PubMed]
17. Fajans SS, Floyd JC, Jr, Tattersall RB, Williamson JR, Pek S, Taylor CI. The various faces of diabetes in the young: changing concepts. Arch Intern Med 1976;136:194–202 [PubMed]
18. Fajans SS. MODY—a model for understanding the pathogeneses and natural history of type II diabetes. Horm Metab Res 1987;19:591–599 [PubMed]
19. Fajans SS, Floyd JC, Jr, Pek S, Conn JW. The course of asymptomatic diabetes in young people, as determined by levels of blood glucose and plasma insulin. Trans Assoc Am Physicians 1969;82:211–224 [PubMed]
20. Fajans SS. Heterogeneity of insulin secretion in type II diabetes. Diabetes Metab Rev 1986;2:347–361 [PubMed]
21. Andreone T, Fajans SS, Rotwein P, Skolnick M, Permutt MA. Insulin gene analysis in a family with maturity-onset diabetes of the young. Diabetes 1985;34:108–114 [PubMed]
22. Elbein SC, Borecki I, Corsetti L, et al. Linkage analysis of the human insulin receptor gene and maturity onset diabetes of the young. Diabetologia 1987;30:641–647 [PubMed]
23. Vinik AJ, Cox NJ, Xiang K, Fajans SS, Bell GI. Linkage studies of maturity onset diabetes of the young—R.W. pedigree. Diabetologia 1988;31:778. [PubMed]
24. Bell GI, Xiang K, Newman MV, et al. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc Natl Acad Sci USA 1991;88:1484–1488 [PubMed]
25. Bowden DW, Gravius TC, Akots G, Fajans SS. Identification of genetic markers flanking the locus for maturity-onset diabetes of the young on human chromosome 20. Diabetes 1992;41:88–92 [PubMed]
26. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature 1996;384:458–460 [PubMed]
27. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 1996;384:455–458 [PubMed]
28. Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:162–164 [PubMed]
29. Hattersley AT, Turner RC, Permutt MA, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307–1310 [PubMed]
30. Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:721–722 [PubMed]
31. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997;17:138–139 [PubMed]
32. Fajans SS, Bell GI, Paz VP, et al. Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1 mutation Pro63fsX60. Transl Res 2010;156:7–14 [PMC free article] [PubMed]
33. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997;17:384–385 [PubMed]
34. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504–2508 [PubMed]
35. Fajans SS, Bell GI. Maturity-onset diabetes of the young: a model for genetic studies of diabetes mellitus. In Diabetes Mellitus: A Fundamental and Clinical Text 2nd ed. LeRoith D, Taylor SF, Olefsky JM, Eds. Philadelphia, PA, J.P. Lippincott Company, 2000, p. 691–705
36. Herman WH, Fajans SS, Ortiz FJ, et al. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes 1994;43:40–46 [PubMed]
37. Byrne MM, Sturis J, Fajans SS, et al. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes 1995;44:699–704 [PubMed]
38. Byrne MM, Sturis J, Clément K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994;93:1120–1130 [PMC free article] [PubMed]
39. Byrne MM, Sturis J, Menzel S, et al. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes 1996;45:1503–1510 [PubMed]
40. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971–980 [PubMed]
41. Fajans SS, Floyd JC, Jr, Knopf RF, Conn FW. Effect of amino acids and proteins on insulin secretion in man. Recent Prog Horm Res 1967;23:617–662 [PubMed]
42. Herman WH, Fajans SS, Smith MJ, Polonsky KS, Bell GI, Halter JB. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4α/MODY1 gene. Diabetes 1997;46:1749–1754 [PubMed]
43. Ilag LL, Tabaei BE, Herman WH, et al. Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4α/MODY1 gene. Diabetes 2000;49:961–968 [PubMed]
44. Lehto M, Bitzén PO, Isomaa B, et al. Mutation in the HNF-4alpha gene affects insulin secretion and triglyceride metabolism. Diabetes 1999;48:423–425 [PubMed]
45. Shih DQ, Dansky HM, Fleisher M, Assmann G, Fajans SS, Stoffel M. Genotype/phenotype relationships in HNF-4α/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes 2000;49:832–837 [PubMed]
46. Richter S, Shih DQ, Pearson ER, et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1α: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003;52:2989–2995 [PubMed]
47. Owen KR, Thanabalasingham G, James TJ, et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010;33:1919–1924 [PMC free article] [PubMed]
48. Fajans SS, Bell GI. Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees. Diabetologia 2006;49:1106–1108 [PubMed]
49. Cuesta-Muñoz AL, Tuomi T, Cobo-Vuilleumier N, et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY). Diabetes Care 2010;33:290–292 [PMC free article] [PubMed]
50. Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007;4:e118. [PMC free article] [PubMed]
51. Fajans SS, Bell GI. Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4α (HNF4A). Diabetologia 2007;50:2600–2601 [PubMed]
52. Voight BF, Scott LJ, Steinthorsdottir V, et al. ; MAGIC investigators; GIANT Consortium Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579–589 [PMC free article] [PubMed]
53. Jafar-Mohammadi B, Groves CJ, Gjesing AP, et al. ; DIAGRAM Consortium A role for coding functional variants in HNF4A in type 2 diabetes susceptibility. Diabetologia 2011;54:111–119 [PMC free article] [PubMed]
54. Fajans SS, Herman WH, Oral EA. Insufficient sensitivity of hemoglobin A(1C) determination in diagnosis or screening of early diabetic states. Metabolism 2011;60:86–91 [PMC free article] [PubMed]
55. Lorini R, Klersy C, d’Annunzio G, et al. ; Italian Society of Pediatric Endocrinology and Diabetology (ISPED) Study Group Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 2009;32:1864–1866 [PMC free article] [PubMed]
56. Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care 2006;29:189–194 [PubMed]
57. Fujimoto K, Ford EL, Tran H, et al. Loss of Nix in Pdx1-deficient mice prevents apoptotic and necrotic β cell death and diabetes. J Clin Invest 2010;120:4031–4039 [PMC free article] [PubMed]
58. American Diabetes Association Standards of medical care in diabetes—2010. Diabetes Care 2010;33:S11–S61 [PMC free article] [PubMed]
59. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009;10(Suppl. 12):33–42 [PubMed]
60. Ellard S, Bellanné-Chantelot C, Hattersley AT.; European Molecular Genetics Quality Network (EMQN) MODY group Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008;51:546–553 [PMC free article] [PubMed]

Articles from Diabetes Care are provided here courtesy of American Diabetes Association